ASH Clinical News September 2015 | Page 68

Minimal Residual Disease the greatest risk for a poor outcome. “It’s very clear that pediatric ALL patients who have high levels of MRD at the end of the first month of therapy – using 10-4 or 0.01 percent as the common definition of ‘high’ MRD – do significantly worse than those that are negative at that point,” Dr. Hunger said. “Most groups and physicians will intensify treatment after the first month for those who are MRD-positive.” But, some believe even earlier testing could be a benefit, as Dr. Pui demonstrated in his recent study in The Lancet Oncology, where patients who tested MRD-positive (>1%) after just 19 days of remission induction therapy had significantly worse 10-year EFS.1 “For most centers, I think the best timing is really two weeks into induction,” Dr. Pui stated. At this point, he explained, falsepositives are unlikely and oncologists can make decisions about whether to back off or intensify treatment even earlier. But measuring MRD at only one time point may not be enough – especially considering the heterogeneity among ALL subtypes. For instance, T-cell patients have a slower response than patients with precursor B-cell ALL, according to Paul Gaynon, MD, profes- “Everybody is comfortable with the idea that MRDpositive patients must get different treatment, but [we don’t know] if giving these patients more therapy improves their outcomes.” —MICHAEL J. BOROWITZ, MD, PhD sor of pediatrics at Children’s Hospital Los Angeles. “In T-cell ALL, many patients were slow responders by day 29 but then rallied by day 85,” he said. “They had good responses and did quite well.”2 According to Dr. Hunger, there is also significant evidence that testing again at later time points could be valuable – particularly for patients who test MRD-positive at the one-month mark. “Research has shown that people who test positive after induction, but test negative at three months do substantially better than those who are still positive at three months,” he said.4 66 ASH Clinical News Many physicians also rely on MRD measurements to evaluate the best timing to perform a stem cell transplantation. If patients are MRDpositive going into transplant, Dr. Borowitz said, data have shown that their outcomes are much worse than patients who are MRD-negative before transplant.5 For this reason, oncologists may want to take MRD into consideration when deciding on whether transplant is needed, as well as thinking about using additional therapy to get patients to an MRD-negative state if transplant is deemed necessary. as an equivalent of relapse (before a morphologic relapse is determined) is that physicians do not want to expose patients to unnecessary morbidity and mortality associated with additional therapy or stem cell transplants. “Until there is more proof that persistent or recurrent MRD during treatment is predictive of impending relapse – highly predictive, not just ‘suggested’ – people are not really willing to act on that information by and large,” Dr. Hunger said. The Search for a New Surrogate Endpoint Continues So, is there a “safe” level of MRD? That is still unclear, but newer technology such as nextgeneration sequencing could provide more answers in the near future. Dr. Hunger, however, cautioned that immunoglobular T-cell receptor-based technologies get down to such a low level of measurement that it is not always possible to distinguish between a pre-leukemic ancestral clone and a fully leukemic clone. “We really do not know what some of these very low levels mean yet,” he said. While we do know that ALL patients who don’t have MRD at earlier points in their therapy tend to have the best prognosis, researchers are still trying to determine the best way to treat patients who appear to be in remission based on morphologic examinations but who still have MRD. Consensus about whether MRD can be used as an endpoint in clinical trials, or whether oncologists should be monitoring MRD to signal relapse, have yet to be reached. Currently, it seems that the unanswered questions surrounding MRD in ALL outweigh the answered ones. Is MRD monitoring in ALL all it’s cracked up to be? There was a common refrain among all of the experts we spoke with: Despite previous and ongoing research, it’s still too soon to call. As research forges ahead, finding the answers to these questions will be the key in ultimately understanding the true power of MRD.—By Jill Sederstrom ● Patients who have MRD do worse than those who don’t – that much is clear. But despite its significant prognostic properties, using MRD as a clinical endpoint is still under dispute. “There are some well-known examples of cases where therapy has improved outcomes but didn’t change MRD,” Dr. Hunger said. “It makes people a little leery about this idea.” For example, an open-label randomized trial comparing the effect of mitoxantrone with idarubicin in children with first relapse of ALL found that, although the mitoxantrone-treated patients had a lower relapse rate, there was no apparent difference in MRD between the two drugs in the intermediate-risk group – leading researchers to believe that the decrease in relapse was unrelated to the kinetics of disease clearance.6 “To enable the quick assessment of the number of new drugs now in the pipeline, study designs are incorporating the use of MRD as a surrogate marker of outcome,” lead author Catriona Parker, PhD, and co-authors wrote. “If we had opted to use such a study design, mitoxantrone would have been discarded.” The hope, Dr. Gaynon said, was that if there was no difference in MRD levels after the one-month time point, there would also be no difference in EFS in the long run, but evidence has failed to support this hypothesis. “Sadly, MRD is not a surrogate for efficacy,” he said. An Early Indicator for Relapse? While researchers tend to agree that MRD has clear prognostic properties, its role after remission in predicting a relapse is less clear. “This is an ongoing research question,” Dr. Pui cautioned. “Nothing has been definitively proven.” MRD appears to be a significant risk factor for relapse in adult patients: A 2009 study published in Blood found that MRD analysis du ring early post-remission therapy improves risk definitions and helps improve risk-oriented treatment strategies. Patients who were MRD-negative had five-year overall survival and disease-free survival rates of 0.75 and 0.72, respectively, compared with rates of just 0.33 and 0.14 in MRD-positive patients. Presence of MRD, then, was the most significant risk factor for relapse, with a hazard ratio of 5.22.7 According to Dr. Hunger, MRD is far from a perfect predictor of relapse: Some patients who are MRD-negative will still relapse, and others who are MRD-positive will not. The main reason for the hesitation to adopt rising MRD levels What We Still Don’t Know References 1. Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16:465-74. 2. Parekh C, Gaynon PS, Abdel-Azim H. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 May 14. [Epub ahead of print] 3. National Cancer Institute. Comparison of laboratory test results of minimal-residual disease in samples from patients with acute myeloid leukemia (NCT01498302). Accessed August 14, 2015 from https://clinicaltrials.gov/ct2/show/ NCT01498302. 4. van Dongen JJM, van der Velden VHJ, Bruggeman M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996-4009. 5. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358:1239-41. 6. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009-17. 7. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153-62. September 2015